Literature DB >> 26136873

Ulinastatin enhances the therapeutic effect of intraperitoneal lavage on severe acute pancreatitis in rats.

Cong Feng1, Xuan Su2, L I Chen3, Xuan Zhou3, Bei Li3, Li-Li Wang3, Fa-Qin Lv4, Tan-Shi Li3.   

Abstract

The present study investigated the therapeutic effect of peritoneal lavage with ulinastatin on the outcome of rats with severe acute pancreatitis (SAP). A total of 110 male Wistar rats were randomly divided into the following groups: Control (C), SAP model (SAP), saline lavage (SL), intravenous ulinastatin (IU) and low-dose (LUL), medium-dose (MUL), high-dose (HUL) and ultrahigh-dose (UHUL) ulinastatin lavage. The treatments were performed immediately subsequent to the establishment of the SAP model. Intraperitoneal lavage with or without ulinastatin was performed for 3 h. Survival time was recorded for 12 h and the median survival time was calculated. Histopathological analyses, and measurements of plasma amylase and lipase levels were performed. Blood pH, lactic acid and base excess were also detected. The LUL, MUL, HUL, UHUL and IU groups showed an increase in the median survival time compared with the SAP group, with the maximal effect observed in the MUL group (P<0.01). The SL, MUL and IU groups showed a reduced activity of amylase and lipase compared with the SAP group. The SL (P<0.01) and the MUL groups (P<0.01) additionally showed a reduction in the lactic acid in arterial blood relative to the SAP group but the IU group did not. The MUL group showed greater improvements in pH (P<0.01) and base excess (P<0.01) versus the SAP group than the SL and IU groups. Furthermore the MUL group demonstrated a more marked reduction in the histological changes in necrosis, edema and inflammation compared with the SL and IU groups. Intraperitoneal lavage with ulinastatin significantly improves the prognosis of SAP in rats.

Entities:  

Keywords:  intraperitoneal lavage; severe acute pancreatitis; ulinastatin

Year:  2015        PMID: 26136873      PMCID: PMC4471762          DOI: 10.3892/etm.2015.2334

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  21 in total

1.  [Early and prolonged peritoneal lavage with laparoscopy in severe acute pancreatitis].

Authors:  G Botoi; A Andercou
Journal:  Chirurgia (Bucur)       Date:  2009 Jan-Feb

2.  Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis.

Authors:  U Leonhardt; F Seidensticker; M Fussek; F Stöckmann; W Creutzfeldt
Journal:  Gut       Date:  1990-08       Impact factor: 23.059

Review 3.  Acute pancreatitis: overview of medical aspects.

Authors:  S Watanabe
Journal:  Pancreas       Date:  1998-04       Impact factor: 3.327

4.  Morphological changes of the pancreas in course of acute pancreatitis during treatment with Ulinastatin.

Authors:  Grzegorz Wallner; Michał Solecki; Ryszard Ziemiakowicz; Grzegorz Ćwik; Przemysław Dyndor; Ryszard Maciejewski
Journal:  Pol Przegl Chir       Date:  2013-03

5.  Human urinary trypsin inhibitor, urinastatin, prevents pancreatic injuries induced by pancreaticobiliary duct obstruction with cerulein stimulation and systemic hypotension in the rat.

Authors:  T Hirano; T Manabe
Journal:  Arch Surg       Date:  1993-12

6.  Effective peritoneal therapy of acute pancreatitis in the rat with glutaryl-trialanin-ethylamide: a novel inhibitor of pancreatic elastase.

Authors:  P Fric; J Slabý; E Kasafírek; P Kocna; J Marek
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

7.  Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis.

Authors:  H Ohnishi; H Kosuzume; Y Ashida; K Kato; I Honjo
Journal:  Dig Dis Sci       Date:  1984-01       Impact factor: 3.199

8.  [Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin].

Authors:  H Matsukawa; A Hara; T Ito; K Fukui; K Sato; M Ichikawa; M Yoshioka; H Seki; K Yamataka; K Takizawa; S Okuda; N Shiraga
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1998-11

9.  Therapeutic regimens in acute experimental hemorrhagic pancreatitis. Effects of hydration, oxygenation, peritoneal lavage, and a potent protease inhibitor.

Authors:  C Niederau; R A Crass; G Silver; L D Ferrell; J H Grendell
Journal:  Gastroenterology       Date:  1988-12       Impact factor: 22.682

10.  Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors.

Authors:  R Berling; A Borgström; K Ohlsson
Journal:  Int J Pancreatol       Date:  1998-08
View more
  3 in total

1.  Associations of MMP-2 and MMP-9 gene polymorphism with ulinastatin efficacy in patients with severe acute pancreatitis.

Authors:  Guo-Dong Zhen; Lian-Bin Zhao; Shan-Shan Wu; Ming-Yu Chen; Zhen-He Li; Sheng-Zhi Zhou; Zhen-Fu Li
Journal:  Biosci Rep       Date:  2017-08-23       Impact factor: 3.840

2.  MMP-2 and MMP-9 gene polymorphisms act as biological indicators for ulinastatin efficacy in patients with severe acute pancreatitis.

Authors:  Lan Ling; Yan Li; Hong Li; Wen Li; Hong-Bo Zhang
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

3.  Effect of peritoneal lavage with ulinastatin on the expression of NF-κB and TNF-α in multiple organs of rats with severe acute pancreatitis.

Authors:  Cong Feng; Bei Li; Li-Li Wang; L I Chen; Xuan Zhou; Fa-Qin Lv; Tan-Shi Li
Journal:  Exp Ther Med       Date:  2015-10-15       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.